PARP Inhibitor Dosing in Older Ovarian Cancer Patients
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies how well older adults (70+) with advanced ovarian cancer tolerate PARP inhibitors in real-world care. It aims to see if the standard dose works for this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 70 years old or older.
- You have advanced ovarian cancer (stage III or IV).
- You have never taken a PARP inhibitor before.
- You are able to swallow pills and attend regular appointments.
- You have no other cancer that was treated within the last 2 years (except for certain minor skin cancers or early-stage cervical or bladder cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study asks people with advanced ovarian cancer about their preferences for treatment with PARP inhibitors (a type of maintenance therapy). The goal is to learn what matters most to patients for their quality of life.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This trial tests whether a supervised exercise program combined with nutrition counseling can help women with advanced ovarian cancer who are taking PARP inhibitor maintenance therapy. It aims to improve quality of life and physical function during treatment.
This study looks at how diet affects outcomes in people with ovarian cancer who are taking PARP inhibitors after initial treatment. Participation involves completing a food frequency questionnaire.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This trial tests whether olaparib (a pill cancer medicine) works better than standard platinum chemotherapy after a second surgery for recurrent ovarian cancer. It’s for people whose cancer returned after initial PARP-inhibitor (PARPi) maintenance and aims to see if treatment can control the cancer for longer with acceptable side effects.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.